Forgot Password

Flat 25% discount on all reports exclusively for July & August 2018

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Pharmaceuticals » HPH-3501016
  • Global Kidney Cancer Drug Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

  • Publish: October 2016 | Report Code: HPH-3501016

* For discount/customization and buying a particular chapter click here or write to us at sales@occamsresearch.com

The global kidney cancer drug market is estimated to reach by USD 4.5 billion at a CAGR of 6.2% till 2022. Kidney is the most important organ in human body. They regulate the blood pressure and serve homeostatic function for maintaining the nutrients and toxins balance in the body of human. They serve as a natural filters of blood, and removes the water soluble wastes and reabsorbing the essential elements from the blood. Since they perform such crucial role, they need constant regeneration of dead nephrons and proper circulation of blood to maintain healthy cell growth due to which kidney are vulnerable to cancerous tumors and metastasis. Renal cell carcinoma which is most common type of renal cancer is toughest to get treated and mainly in advanced stages. In early years 1980’s the treatment for renal cancer was done by removing the kidneys by surgery. Later it gets progressed by removal of the part of the kidney which is affected by tumor and is known as laparoscopic. Kidney cancer drug are normally given to the patients who has reached to stage four renal cell carcinoma. Nowadays different mechanism is being performed for the treatment of cancer due to approved drugs for renal cancer. Some of these drugs are vascular endothelial growth factor inhibitor, cytokine therapy, angiogenesis inhibitor and immune modulation therapy. The major reason for kidney cancer is von hippellindau (VHL) syndrome, smoking, obesity, high blood pressure, occupational exposure, long term dialysis. The symptoms of renal cancer include blood in the urine, getting lump or mass in sides or abdomen, weight loss, lethargy and fever.

Rising prevalence of lifestyle tempted diseases such as excess of drinking and smoking along with chronic diseases such as cancer and renal tumor are some of the major factor which is responsible for driving the market of kidney cancer drug. Along with this, rising geriatric population is also impacting the market positively as the people of this age group are more likely to have chronic diseases. Additionally, the renal cancer drug is preferred by clinicians and patients over therapies. The cancer drugs are life long term treatment regiments which are available for patients who are suffering from advanced stage of metastatic tumor.

The mergers, acquisition and expansions made by the companies are the key strategy which is adopted to boost the kidney cancer drug market. Several approvals which are getting received for the kidney cancer drugs globally are also a prime factor for fueling the growth of kidney cancer drug market.

The market includes several driving factors for it, but although there are some of the challenges which are faced by kidney cancer drug market such as rising preference of consumer for geriatric drugs is negatively impacting the market. In addition, high prices for branded drugs are responsible for hampering the growth of the market of kidney cancer drug.

The kidney cancer drug market is segmented on the basis of type, on the basis of brand, and on the basis of geography. On the basis of type the kidney cancer drug is sub segmented in to clear cell, papillary (type 1 and type 2), chromophobe, oncocytic, and collecting duct. On the basis of brand the kidney cancer drug market is sub segmented in to nexavar (sorafenib), sutent (sunitinib), afinitor(Everolimus), votrient (pazopanib) , Avastin (Bevacizumab),  Inlyta (Axitinib),  Torisel (Temsirolimus), and Proleukin (Aldesleukin).

On the basis of the geography the kidney cancer drug market is mainly segmented into North America, Latin America, Europe, APAC and the rest of the world. North America has the largest market share for kidney cancer drug globally. Increase in kidney diseases and kidney cancer are responsible mainly for the driving the market growth in this region.

However Asia pacific is also foreseen to have most effective growth during the forecast period. Rising level of patient awareness, lower cost production of drugs and increasing patients suffering from kidney diseases such as kidney cell carcinoma are estimated to drive the market growth in this region during the forecast period.

The major key players in kidney cancer drug market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Onyx Pharmaceuticals Inc. (US), Bayer AG (Germany), Active Biotech AB (Sweden), Novartis AG (Switzerland), Amgen (US), Genentech, Inc. (US), and Cipla Limited (India). In these market expansions, mergers and acquisition are some of the key strategies adopted by the companies to sustain in the long run. Further, growing need kidney cancer drugsupply across numerous regions is instigating manufacturers for improvising the quality in all aspects of production and distribution.

In January 2016, Novartis AG had unlicensed agreement collaboration with Surface oncology to grow immune-oncology pipeline.

1.            INTRODUCTION

1.1.         EXECUTIVE SUMMARY

1.2.         ESTIMATION METHODOLOGY

2.            MARKET OVERVIEW

2.1.         GLOBAL FINTECH BLOCKCHAIN MARKET: EVOLUTION & TRANSITION

2.2.         MARKET DEFINITION & SCOPE

2.3.         INDUSTRY STRUCTURE

2.4.         TOTAL MARKET ANALYSIS

2.4.1.     TOP 5 FINDINGS

2.4.2.     TOP 5 OPPORTUNITY MARKETS

2.4.3.     TOP 5 COMPANIES

2.4.4.     TOP 3 COMPETITIVE STRATEGIES

2.5.         ESTIMATION ANALYSIS

2.6.         STRATEGIC ANALYSIS

2.6.1.     INVESTMENT VS. ADOPTION MODEL

2.6.2.     360-DEGREE INDUSTRY ANALYSIS

2.6.3.     PORTERS 5 FORCE MODEL

2.6.4.     SEE-SAW ANALYSIS

2.6.5.     CONSUMER ANALYSIS AND KEY BUYING CRITERIA

2.7.         COMPETITIVE ANALYSIS

2.7.1.     KEY STRATEGIES & ANALYSIS

2.7.2.     MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS

2.8.         STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS

2.8.1.     INVESTMENT OPPORTUNITIES BY REGIONS

2.8.2.     OPPORTUNITIES IN EMERGING APPLICATIONS

2.8.3.     INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3.            MARKET DETERMINANTS

3.1.         MARKET DRIVERS

3.1.1.     RISING CRYPTOCURRENCY MARKET CAP AND ICO

3.1.2.     FASTER TRANSACTIONS

3.1.3.     HIGH COMPATIBILITY WITH FINANCIAL SERVICES INDUSTRY ECOSYSTEM

3.1.4.     REDUCED TOTAL COST OF OWNERSHIP

3.2.         MARKET RESTRAINTS

3.2.1.     UNCERTAIN REGULATORY FRAMEWORKS AND STANDARDS

3.2.2.     LACK OF BLOCKCHAIN USE CASES AND APPLICATIONS

3.3.         MARKET OPPORTUNITIES

3.3.1.     INCREASING ADOPTION OF BLOCKCHAIN FOR PAYMENTS, SMART CONTRACTS, AND DIGITAL IDENTITIES

3.3.2.     EMERGENCE OF PROGRAMMABLE BLOCKCHAIN PLATFORMS

3.4.           MARKET CHALLENGES

3.4.1.     ISSUES REGARDING SECURITY, PRIVACY, AND CONTROL

3.4.2.     SCALABILITY AND LATENCY CHALLENGES

 4 GLOBAL KIDNEY CANCER DRUG

 4.1.        MARKET DEFINITION AND SCOPE

4.2.         DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.3.         COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.4.         OPPORTUNITY MATRIX

4.5.         MARKET SEGMENTATION

4.5.1 GLOBAL CLEAR CELL MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

4.5.2 GLOBAL PAPILLARY MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

4.5.3 GLOBAL CHROMOPHOBE MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

4.5.4 GLOBAL ONCOCYTIC MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

4.5.5 GLOBAL COLLECTING DUCT MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

5 GLOBAL KIDNEY CANCER DRUG MARKET BY BRAND

5.1.         MARKET DEFINITION AND SCOPE

5.2.         DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

5.3.         COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

5.4.         OPPORTUNITY MATRIX

5.5.         MARKET SEGMENTATION

5.5.1 GLOBAL NEXAVAR (SORAFENIB)MARKET

5.5.1.1 ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

5.5.2 GLOBAL AFINITOR (EVEROLIMUS) MARKET

5.5.2.1                ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.2.3. KEY PLAYERS & KEY PRODUCTS

4.5.2.4. KEY CONCLUSIONS

5.5.3 GLOBAL VOTRIENT (PAZOPANIB) MARKET

5.5.3.1       ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.3.3. KEY PLAYERS & KEY PRODUCTS

4.5.3.4. KEY CONCLUSIONS

5.5.4 GLOBAL AVASTIN (BEVACIZUMAB) MARKET

5.5.4.1         ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.3.3. KEY PLAYERS & KEY PRODUCTS

4.5.3.4. KEY CONCLUSIONS

5.5.5 GLOBAL INLYTA (AXITINIB) MARKET

5.5.5.1        ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.5.3. KEY PLAYERS & KEY PRODUCTS

4.5.5.4. KEY CONCLUSIONS

5.5.6 GLOBAL TORISEL (TEMSIROLIMUS) MARKET

5.5.6.1         ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.6.3. KEY PLAYERS & KEY PRODUCTS

4.5.6.4. KEY CONCLUSIONS

5.5.7 GLOBAL PROLEUKIN (ALDESLEUKIN) MARKET

5.5.7.1 ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.7.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.7.3. KEY PLAYERS & KEY PRODCUTS

4.5.7.4         KEY CONCLUSION

 

7.            COMPETITIVE LANDSCAPE

7.1.         KEY STRATEGIES

7.1.1.     LIST OF MERGERS AND ACQUISITION

7.1.2.     LIST OF JOINT VENTURES

7.1.3.     LIST OF PRODUCT LAUNCHES

7.1.4.     LIST OF PARTNERSHIPS

8.            GEOGRAPHIC ANALYSIS

8.1.         DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

8.2.         COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

8.3.         OPPORTUNITY MATRIX

8.4.         GLOBAL FINTECH BLOCKCHAIN MARKET BY REGION 2015-2024 

8.4.1.     NORTH AMERICA

8.4.1.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)

8.4.1.2. TOP COUNTRY ANALYSIS

8.4.1.2.1.              U.S.

8.4.1.2.1.1.          MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

8.4.1.2.1.2.          KEY PLAYERS & KEY PRODUCTS

8.4.1.2.1.3.          KEY CONCLUSIONS

8.4.1.2.2.              CANADA

8.4.1.2.2.1.          MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

8.4.1.2.2.2.          KEY PLAYERS & KEY PRODUCTS

8.4.1.2.2.3.          KEY CONCLUSIONS

8.4.2.     EUROPE

8.4.2.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)

8.4.2.2. TOP COUNTRY ANALYSIS

 

9 COMPANY PROFILE

9.1     ACTIVE BIOTECH AB (SWEDEN)

9.1.1   OVERVIEW

10.1.2.  PRODUCT PORTFOLIO

10.1.3.  STRATEGIC INITIATIVES

10.1.4.  SCOT ANALYSIS

10.1.5.  STRATEGIC ANALYSIS

9.2   AMGEN (US),

9.2.1 ACTIVE BIOTECH AB (SWEDEN)

9.2.1   OVERVIEW

9.2.2.     PRODUCT PORTFOLIO

9.1.3.     STRATEGIC INITIATIVES

9.1.4.     SCOT ANALYSIS

9.1.5.     STRATEGIC ANALYSIS

 9.3    BAYER AG (GERMANY)

9.3.1 ACTIVE BIOTECH AB (SWEDEN)

9.3.1   OVERVIEW

9.3.2.     PRODUCT PORTFOLIO

9.3.3.     STRATEGIC INITIATIVES

9.3.4.     SCOT ANALYSIS

9.3.5.     STRATEGIC ANALYSIS

9.4 CIPLA LIMITED (INDIA)

9.4.1 ACTIVE BIOTECH AB (SWEDEN)

9.4.1   OVERVIEW

9.4.2.     PRODUCT PORTFOLIO

9.4.3.     STRATEGIC INITIATIVES

9.4.4.     SCOT ANALYSIS

9.4.5.     STRATEGIC ANALYSIS

9.5 F. HOFFMANN-LA ROCHE AG (SWITZERLAND),

9.5.1ACTIVE BIOTECH AB (SWEDEN)

9.5.1   OVERVIEW

9.5.2.     PRODUCT PORTFOLIO

9.5.3.     STRATEGIC INITIATIVES

9.5.4.     SCOT ANALYSIS

9.5.5.     STRATEGIC ANALYSIS

 9.6 GENENTECH, INC. (US)

9.6.1 OVERVIEW

9.6.2.     PRODUCT PORTFOLIO

9.6.3.     STRATEGIC INITIATIVES

9.6.4.     SCOT ANALYSIS

9.6.5.     STRATEGIC ANALYSIS

9.7 GLAXOSMITHKLINE PLC (UK)

9.7.1   OVERVIEW

9.7.2.     PRODUCT PORTFOLIO

9.7.3.     STRATEGIC INITIATIVES

9.7.4.     SCOT ANALYSIS

9.7.5.     STRATEGIC ANALYSIS

9.8 NOVARTIS AG (SWITZERLAND)

9.8.1   OVERVIEW

9.8.2.     PRODUCT PORTFOLIO

9.8.3.     STRATEGIC INITIATIVES

9.8.4.     SCOT ANALYSIS

9.8.5.     STRATEGIC ANALYSIS

9.9 ONYX PHARMACEUTICALS INC. (US)

9.9.1 OVERVIEW

9.9.2.     PRODUCT PORTFOLIO

9.9.3.     STRATEGIC INITIATIVES

9.9.4.     SCOT ANALYSIS

9.9.5.     STRATEGIC ANALYSIS

 9.10 PFIZER, INC. (US)

9.10.1 OVERVIEW

9.10.2.  PRODUCT PORTFOLIO

9.10.3.  STRATEGIC INITIATIVES

9.10.4.  SCOT ANALYSIS

9.10.5.  STRATEGIC ANALYSIS

 9.11 ABBOTT LABORATORIES

9.11.1 OVERVIEW

9.11.2.  PRODUCT PORTFOLIO

9.11.3.  STRATEGIC INITIATIVES

9.11.4.  SCOT ANALYSIS

9.11.5.  STRATEGIC ANALYSIS

9.12 AVEO PHARMACEUTICALS

9.12.1 OVERVIEW

9.12.2.  PRODUCT PORTFOLIO

9.12.3.  STRATEGIC INITIATIVES

9.12.4.  SCOT ANALYSIS

9.12.5.  STRATEGIC ANALYSIS

 9.13 IMMATICS BIOTECHNOLOGIES

9.13.1 OVERVIEW

9.13.2.  PRODUCT PORTFOLIO

9.13.3.  STRATEGIC INITIATIVES

9.13.4.  SCOT ANALYSIS

9.13.5.  STRATEGIC ANALYSIS

9.14 PROMETHEUS LABORATORIES

9.14.1        OVERVIEW

9.14.2.  PRODUCT PORTFOLIO

9.14.3.  STRATEGIC INITIATIVES

9.14.4.  SCOT ANALYSIS

9.14.5.  STRATEGIC ANALYSIS

9.15 EXELIXIS

9.15.1     OVERVIEW

9.15.2.  PRODUCT PORTFOLIO

9.15.3.  STRATEGIC INITIATIVES

9.15.4.  SCOT ANALYSIS

9.15.5.  STRATEGIC ANALYIS 

 

LIST OF FIGURE

1. GLOBAL KIDNEY CANCER DRUG BY TYPE 2015-2024 ($ MILLION)

2. GLOBAL CLEAR CELL TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

3. GLOBAL PAPILLARY TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

4 GLOBAL CHROMOPHOBE TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

5 GLOBAL ONCOCYTIC TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

6 GLOBAL COLLECTING DUCT TYPE MARKET   BY GEOGRAPHY 2015-2024 ($ MILLION)

7 GLOBAL KIDNEY CANCER DRUG BY BRAND MARKET 2015-2024 ($ MILLION)

8 GLOBAL NEXAVAR (SORAFENIB) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

9 GLOBAL SUTENT (SUNITINIB) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

10 GLOBAL AFINITOR (EVEROLIMUS) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

11 GLOBAL VOTRIENT (PAZOPANIB) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

12 GLOBAL AVASTIN (BEVACIZUMAB) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

13 GLOBAL INLYTA (AXITINIB) TYPE MARKET BY GEOGRAPPHY 2015-2024 ($ MILLION)

14 GLOBAL TORISEL (TEMSIROLIMUS) TYPE MARKET BY GEOGRAPPHY 2015-2024 ($ MILLION)

15 GLOBAL PROLEUKIN (ALDESLEUKIN) TYPE MARKET BY GEOGRAPPHY 2015-2024 ($ MILLION)

 

16      NORTH AMERICA KIDNEY CANCER MARKET 2015-2024 ($ MILLION)

21.          EUROPE KIDNEY CANCER 2015-2024 ($ MILLION)

22.          ASIA PACIFIC KIDNEY CANCER MARKET 2015-2024 ($ MILLION)

23.          REST OF THE WORLD KIDNEY CANCER MARKET 2015-2024 ($ MILLION)

25      NORTH AMERICA CLEAR CELL MARKET BY TYPE 2015-2024 ($ MILLION)

26      EUROPE CLEAR CELL MARKET BY TYPE 2015-2024 ($ MILLION)

27      ASIA PACIFIC CLEAR CELL MARKET BY TYPE 2015-2024 ($ MILLION)

28      REST OF THE WORLD CLEAR CELL MARKET BY TYPE 2015-2024 ($ MILLION)

29      NORTH AMERICA CLEAR CELL MARKET BY BRAND 2015-2024 ($ MILLION)

30      EUROPE CLEAR CELL MARKET BY BRAND 2015-2024 ($ MILLION)

31      ASIA PACIFIC CLEAR CELL MARKET BY BRAND 2015-2024 ($ MILLION)

32      REST OF THE WORLD CLEAR CELL MARKET BY BRAND 2015-2024 ($ MILLION)

33      UNITED STATES KIDNEY CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

34      CANADA KIDNEY CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

35      UK CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

36      UK CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

37      FRANCE CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

38      FRANCE CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

39      GERMANY CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

40      GERMANY CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

41      SPAIN CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

42      SPAIN CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

43      ROE CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

44      ROE CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

45      CHINA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

46      CHINA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

47      INDIA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

48      INDIA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

49      JAPAN CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

41      JAPAN CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

42      AUSTRALIA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

43      AUSTRALIA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

41      ROAPAC CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

42      ROAPAC CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

43      LATIN AMERICA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

44      LATIN AMERICA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

45      MENA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

46      MENA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

 

LIST OF FIGURE

1   GLOBAL CLEAR CELL MARKET TYPE MARKET 2015-2024 ($ MILLION)

2   GLOBAL PAPILLARY MARKET TYPE MARKET 2015-2024 ($ MILLION)

3   GLOBAL CHROMOPHOBE MARKET TYPE MARKET 2015-2024 ($ MILLION)

4   GLOBAL ONCOCYTIC MARKET TYPE MARKET 2015-2024 ($ MILLION)

5   GLOBAL COLLECTING DUCT MARKET TYPE MARKET 2015-2024 ($ MILLION)

6   GLOBAL NEXAVAR (SORAFENIB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

7   GLOBAL SUTENT (SUNITINIB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

8   GLOBAL AFINITOR (EVEROLIMUS) MARKET BRAND MARKET 2015-2024 ($ MILLION)

9   GLOBAL VOTRIENT (PAZOPANIB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

10 GLOBAL AVASTIN (BEVACIZUMAB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

11 GLOBAL INLYTA (AXITINIB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

12 GLOBAL TORISEL (TEMSIROLIMUS) MARKET   BRAND MARKET 2015-2024 ($ MILLION)

13 GLOBAL PROLEUKIN (ALDESLEUKIN) MARKET BRAND MARKET 2015-2024 ($ MILLION)

14 UNITED STATES CANCER DRUG MARKET 2015-2024 ($ MILLION)

15 CANADA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

16 UNITED KINGDOM KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

17 FRANCE KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

18 GERMANY KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

19 SPAIN KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

20 ROE KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

21 CHINA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

22 INDIA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

23 JAPAN KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

24 AUSTRALIA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

25 ROAPAC KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

26 LATIN AMERICA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

27 MENA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample


UPCOMING REPORTS

No upcoming reports available under this subcategory.

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Pharmaceuticals » HPH-3501016
  • Global Kidney Cancer Drug Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

  • Publish: October 2016 | Report Code: HPH-3501016

* For discount/customization and buying a particular chapter click here or write to us at sales@occamsresearch.com

The global kidney cancer drug market is estimated to reach by USD 4.5 billion at a CAGR of 6.2% till 2022. Kidney is the most important organ in human body. They regulate the blood pressure and serve homeostatic function for maintaining the nutrients and toxins balance in the body of human. They serve as a natural filters of blood, and removes the water soluble wastes and reabsorbing the essential elements from the blood. Since they perform such crucial role, they need constant regeneration of dead nephrons and proper circulation of blood to maintain healthy cell growth due to which kidney are vulnerable to cancerous tumors and metastasis. Renal cell carcinoma which is most common type of renal cancer is toughest to get treated and mainly in advanced stages. In early years 1980’s the treatment for renal cancer was done by removing the kidneys by surgery. Later it gets progressed by removal of the part of the kidney which is affected by tumor and is known as laparoscopic. Kidney cancer drug are normally given to the patients who has reached to stage four renal cell carcinoma. Nowadays different mechanism is being performed for the treatment of cancer due to approved drugs for renal cancer. Some of these drugs are vascular endothelial growth factor inhibitor, cytokine therapy, angiogenesis inhibitor and immune modulation therapy. The major reason for kidney cancer is von hippellindau (VHL) syndrome, smoking, obesity, high blood pressure, occupational exposure, long term dialysis. The symptoms of renal cancer include blood in the urine, getting lump or mass in sides or abdomen, weight loss, lethargy and fever.

Rising prevalence of lifestyle tempted diseases such as excess of drinking and smoking along with chronic diseases such as cancer and renal tumor are some of the major factor which is responsible for driving the market of kidney cancer drug. Along with this, rising geriatric population is also impacting the market positively as the people of this age group are more likely to have chronic diseases. Additionally, the renal cancer drug is preferred by clinicians and patients over therapies. The cancer drugs are life long term treatment regiments which are available for patients who are suffering from advanced stage of metastatic tumor.

The mergers, acquisition and expansions made by the companies are the key strategy which is adopted to boost the kidney cancer drug market. Several approvals which are getting received for the kidney cancer drugs globally are also a prime factor for fueling the growth of kidney cancer drug market.

The market includes several driving factors for it, but although there are some of the challenges which are faced by kidney cancer drug market such as rising preference of consumer for geriatric drugs is negatively impacting the market. In addition, high prices for branded drugs are responsible for hampering the growth of the market of kidney cancer drug.

The kidney cancer drug market is segmented on the basis of type, on the basis of brand, and on the basis of geography. On the basis of type the kidney cancer drug is sub segmented in to clear cell, papillary (type 1 and type 2), chromophobe, oncocytic, and collecting duct. On the basis of brand the kidney cancer drug market is sub segmented in to nexavar (sorafenib), sutent (sunitinib), afinitor(Everolimus), votrient (pazopanib) , Avastin (Bevacizumab),  Inlyta (Axitinib),  Torisel (Temsirolimus), and Proleukin (Aldesleukin).

On the basis of the geography the kidney cancer drug market is mainly segmented into North America, Latin America, Europe, APAC and the rest of the world. North America has the largest market share for kidney cancer drug globally. Increase in kidney diseases and kidney cancer are responsible mainly for the driving the market growth in this region.

However Asia pacific is also foreseen to have most effective growth during the forecast period. Rising level of patient awareness, lower cost production of drugs and increasing patients suffering from kidney diseases such as kidney cell carcinoma are estimated to drive the market growth in this region during the forecast period.

The major key players in kidney cancer drug market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Onyx Pharmaceuticals Inc. (US), Bayer AG (Germany), Active Biotech AB (Sweden), Novartis AG (Switzerland), Amgen (US), Genentech, Inc. (US), and Cipla Limited (India). In these market expansions, mergers and acquisition are some of the key strategies adopted by the companies to sustain in the long run. Further, growing need kidney cancer drugsupply across numerous regions is instigating manufacturers for improvising the quality in all aspects of production and distribution.

In January 2016, Novartis AG had unlicensed agreement collaboration with Surface oncology to grow immune-oncology pipeline.

1.            INTRODUCTION

1.1.         EXECUTIVE SUMMARY

1.2.         ESTIMATION METHODOLOGY

2.            MARKET OVERVIEW

2.1.         GLOBAL FINTECH BLOCKCHAIN MARKET: EVOLUTION & TRANSITION

2.2.         MARKET DEFINITION & SCOPE

2.3.         INDUSTRY STRUCTURE

2.4.         TOTAL MARKET ANALYSIS

2.4.1.     TOP 5 FINDINGS

2.4.2.     TOP 5 OPPORTUNITY MARKETS

2.4.3.     TOP 5 COMPANIES

2.4.4.     TOP 3 COMPETITIVE STRATEGIES

2.5.         ESTIMATION ANALYSIS

2.6.         STRATEGIC ANALYSIS

2.6.1.     INVESTMENT VS. ADOPTION MODEL

2.6.2.     360-DEGREE INDUSTRY ANALYSIS

2.6.3.     PORTERS 5 FORCE MODEL

2.6.4.     SEE-SAW ANALYSIS

2.6.5.     CONSUMER ANALYSIS AND KEY BUYING CRITERIA

2.7.         COMPETITIVE ANALYSIS

2.7.1.     KEY STRATEGIES & ANALYSIS

2.7.2.     MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS

2.8.         STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS

2.8.1.     INVESTMENT OPPORTUNITIES BY REGIONS

2.8.2.     OPPORTUNITIES IN EMERGING APPLICATIONS

2.8.3.     INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3.            MARKET DETERMINANTS

3.1.         MARKET DRIVERS

3.1.1.     RISING CRYPTOCURRENCY MARKET CAP AND ICO

3.1.2.     FASTER TRANSACTIONS

3.1.3.     HIGH COMPATIBILITY WITH FINANCIAL SERVICES INDUSTRY ECOSYSTEM

3.1.4.     REDUCED TOTAL COST OF OWNERSHIP

3.2.         MARKET RESTRAINTS

3.2.1.     UNCERTAIN REGULATORY FRAMEWORKS AND STANDARDS

3.2.2.     LACK OF BLOCKCHAIN USE CASES AND APPLICATIONS

3.3.         MARKET OPPORTUNITIES

3.3.1.     INCREASING ADOPTION OF BLOCKCHAIN FOR PAYMENTS, SMART CONTRACTS, AND DIGITAL IDENTITIES

3.3.2.     EMERGENCE OF PROGRAMMABLE BLOCKCHAIN PLATFORMS

3.4.           MARKET CHALLENGES

3.4.1.     ISSUES REGARDING SECURITY, PRIVACY, AND CONTROL

3.4.2.     SCALABILITY AND LATENCY CHALLENGES

 4 GLOBAL KIDNEY CANCER DRUG

 4.1.        MARKET DEFINITION AND SCOPE

4.2.         DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.3.         COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.4.         OPPORTUNITY MATRIX

4.5.         MARKET SEGMENTATION

4.5.1 GLOBAL CLEAR CELL MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

4.5.2 GLOBAL PAPILLARY MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

4.5.3 GLOBAL CHROMOPHOBE MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

4.5.4 GLOBAL ONCOCYTIC MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

4.5.5 GLOBAL COLLECTING DUCT MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

5 GLOBAL KIDNEY CANCER DRUG MARKET BY BRAND

5.1.         MARKET DEFINITION AND SCOPE

5.2.         DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

5.3.         COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

5.4.         OPPORTUNITY MATRIX

5.5.         MARKET SEGMENTATION

5.5.1 GLOBAL NEXAVAR (SORAFENIB)MARKET

5.5.1.1 ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

5.5.2 GLOBAL AFINITOR (EVEROLIMUS) MARKET

5.5.2.1                ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.2.3. KEY PLAYERS & KEY PRODUCTS

4.5.2.4. KEY CONCLUSIONS

5.5.3 GLOBAL VOTRIENT (PAZOPANIB) MARKET

5.5.3.1       ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.3.3. KEY PLAYERS & KEY PRODUCTS

4.5.3.4. KEY CONCLUSIONS

5.5.4 GLOBAL AVASTIN (BEVACIZUMAB) MARKET

5.5.4.1         ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.3.3. KEY PLAYERS & KEY PRODUCTS

4.5.3.4. KEY CONCLUSIONS

5.5.5 GLOBAL INLYTA (AXITINIB) MARKET

5.5.5.1        ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.5.3. KEY PLAYERS & KEY PRODUCTS

4.5.5.4. KEY CONCLUSIONS

5.5.6 GLOBAL TORISEL (TEMSIROLIMUS) MARKET

5.5.6.1         ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.6.3. KEY PLAYERS & KEY PRODUCTS

4.5.6.4. KEY CONCLUSIONS

5.5.7 GLOBAL PROLEUKIN (ALDESLEUKIN) MARKET

5.5.7.1 ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.7.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

4.5.7.3. KEY PLAYERS & KEY PRODCUTS

4.5.7.4         KEY CONCLUSION

 

7.            COMPETITIVE LANDSCAPE

7.1.         KEY STRATEGIES

7.1.1.     LIST OF MERGERS AND ACQUISITION

7.1.2.     LIST OF JOINT VENTURES

7.1.3.     LIST OF PRODUCT LAUNCHES

7.1.4.     LIST OF PARTNERSHIPS

8.            GEOGRAPHIC ANALYSIS

8.1.         DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

8.2.         COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

8.3.         OPPORTUNITY MATRIX

8.4.         GLOBAL FINTECH BLOCKCHAIN MARKET BY REGION 2015-2024 

8.4.1.     NORTH AMERICA

8.4.1.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)

8.4.1.2. TOP COUNTRY ANALYSIS

8.4.1.2.1.              U.S.

8.4.1.2.1.1.          MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

8.4.1.2.1.2.          KEY PLAYERS & KEY PRODUCTS

8.4.1.2.1.3.          KEY CONCLUSIONS

8.4.1.2.2.              CANADA

8.4.1.2.2.1.          MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)

8.4.1.2.2.2.          KEY PLAYERS & KEY PRODUCTS

8.4.1.2.2.3.          KEY CONCLUSIONS

8.4.2.     EUROPE

8.4.2.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)

8.4.2.2. TOP COUNTRY ANALYSIS

 

9 COMPANY PROFILE

9.1     ACTIVE BIOTECH AB (SWEDEN)

9.1.1   OVERVIEW

10.1.2.  PRODUCT PORTFOLIO

10.1.3.  STRATEGIC INITIATIVES

10.1.4.  SCOT ANALYSIS

10.1.5.  STRATEGIC ANALYSIS

9.2   AMGEN (US),

9.2.1 ACTIVE BIOTECH AB (SWEDEN)

9.2.1   OVERVIEW

9.2.2.     PRODUCT PORTFOLIO

9.1.3.     STRATEGIC INITIATIVES

9.1.4.     SCOT ANALYSIS

9.1.5.     STRATEGIC ANALYSIS

 9.3    BAYER AG (GERMANY)

9.3.1 ACTIVE BIOTECH AB (SWEDEN)

9.3.1   OVERVIEW

9.3.2.     PRODUCT PORTFOLIO

9.3.3.     STRATEGIC INITIATIVES

9.3.4.     SCOT ANALYSIS

9.3.5.     STRATEGIC ANALYSIS

9.4 CIPLA LIMITED (INDIA)

9.4.1 ACTIVE BIOTECH AB (SWEDEN)

9.4.1   OVERVIEW

9.4.2.     PRODUCT PORTFOLIO

9.4.3.     STRATEGIC INITIATIVES

9.4.4.     SCOT ANALYSIS

9.4.5.     STRATEGIC ANALYSIS

9.5 F. HOFFMANN-LA ROCHE AG (SWITZERLAND),

9.5.1ACTIVE BIOTECH AB (SWEDEN)

9.5.1   OVERVIEW

9.5.2.     PRODUCT PORTFOLIO

9.5.3.     STRATEGIC INITIATIVES

9.5.4.     SCOT ANALYSIS

9.5.5.     STRATEGIC ANALYSIS

 9.6 GENENTECH, INC. (US)

9.6.1 OVERVIEW

9.6.2.     PRODUCT PORTFOLIO

9.6.3.     STRATEGIC INITIATIVES

9.6.4.     SCOT ANALYSIS

9.6.5.     STRATEGIC ANALYSIS

9.7 GLAXOSMITHKLINE PLC (UK)

9.7.1   OVERVIEW

9.7.2.     PRODUCT PORTFOLIO

9.7.3.     STRATEGIC INITIATIVES

9.7.4.     SCOT ANALYSIS

9.7.5.     STRATEGIC ANALYSIS

9.8 NOVARTIS AG (SWITZERLAND)

9.8.1   OVERVIEW

9.8.2.     PRODUCT PORTFOLIO

9.8.3.     STRATEGIC INITIATIVES

9.8.4.     SCOT ANALYSIS

9.8.5.     STRATEGIC ANALYSIS

9.9 ONYX PHARMACEUTICALS INC. (US)

9.9.1 OVERVIEW

9.9.2.     PRODUCT PORTFOLIO

9.9.3.     STRATEGIC INITIATIVES

9.9.4.     SCOT ANALYSIS

9.9.5.     STRATEGIC ANALYSIS

 9.10 PFIZER, INC. (US)

9.10.1 OVERVIEW

9.10.2.  PRODUCT PORTFOLIO

9.10.3.  STRATEGIC INITIATIVES

9.10.4.  SCOT ANALYSIS

9.10.5.  STRATEGIC ANALYSIS

 9.11 ABBOTT LABORATORIES

9.11.1 OVERVIEW

9.11.2.  PRODUCT PORTFOLIO

9.11.3.  STRATEGIC INITIATIVES

9.11.4.  SCOT ANALYSIS

9.11.5.  STRATEGIC ANALYSIS

9.12 AVEO PHARMACEUTICALS

9.12.1 OVERVIEW

9.12.2.  PRODUCT PORTFOLIO

9.12.3.  STRATEGIC INITIATIVES

9.12.4.  SCOT ANALYSIS

9.12.5.  STRATEGIC ANALYSIS

 9.13 IMMATICS BIOTECHNOLOGIES

9.13.1 OVERVIEW

9.13.2.  PRODUCT PORTFOLIO

9.13.3.  STRATEGIC INITIATIVES

9.13.4.  SCOT ANALYSIS

9.13.5.  STRATEGIC ANALYSIS

9.14 PROMETHEUS LABORATORIES

9.14.1        OVERVIEW

9.14.2.  PRODUCT PORTFOLIO

9.14.3.  STRATEGIC INITIATIVES

9.14.4.  SCOT ANALYSIS

9.14.5.  STRATEGIC ANALYSIS

9.15 EXELIXIS

9.15.1     OVERVIEW

9.15.2.  PRODUCT PORTFOLIO

9.15.3.  STRATEGIC INITIATIVES

9.15.4.  SCOT ANALYSIS

9.15.5.  STRATEGIC ANALYIS 

 

LIST OF FIGURE

1. GLOBAL KIDNEY CANCER DRUG BY TYPE 2015-2024 ($ MILLION)

2. GLOBAL CLEAR CELL TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

3. GLOBAL PAPILLARY TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

4 GLOBAL CHROMOPHOBE TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

5 GLOBAL ONCOCYTIC TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

6 GLOBAL COLLECTING DUCT TYPE MARKET   BY GEOGRAPHY 2015-2024 ($ MILLION)

7 GLOBAL KIDNEY CANCER DRUG BY BRAND MARKET 2015-2024 ($ MILLION)

8 GLOBAL NEXAVAR (SORAFENIB) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

9 GLOBAL SUTENT (SUNITINIB) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

10 GLOBAL AFINITOR (EVEROLIMUS) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

11 GLOBAL VOTRIENT (PAZOPANIB) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

12 GLOBAL AVASTIN (BEVACIZUMAB) TYPE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)

13 GLOBAL INLYTA (AXITINIB) TYPE MARKET BY GEOGRAPPHY 2015-2024 ($ MILLION)

14 GLOBAL TORISEL (TEMSIROLIMUS) TYPE MARKET BY GEOGRAPPHY 2015-2024 ($ MILLION)

15 GLOBAL PROLEUKIN (ALDESLEUKIN) TYPE MARKET BY GEOGRAPPHY 2015-2024 ($ MILLION)

 

16      NORTH AMERICA KIDNEY CANCER MARKET 2015-2024 ($ MILLION)

21.          EUROPE KIDNEY CANCER 2015-2024 ($ MILLION)

22.          ASIA PACIFIC KIDNEY CANCER MARKET 2015-2024 ($ MILLION)

23.          REST OF THE WORLD KIDNEY CANCER MARKET 2015-2024 ($ MILLION)

25      NORTH AMERICA CLEAR CELL MARKET BY TYPE 2015-2024 ($ MILLION)

26      EUROPE CLEAR CELL MARKET BY TYPE 2015-2024 ($ MILLION)

27      ASIA PACIFIC CLEAR CELL MARKET BY TYPE 2015-2024 ($ MILLION)

28      REST OF THE WORLD CLEAR CELL MARKET BY TYPE 2015-2024 ($ MILLION)

29      NORTH AMERICA CLEAR CELL MARKET BY BRAND 2015-2024 ($ MILLION)

30      EUROPE CLEAR CELL MARKET BY BRAND 2015-2024 ($ MILLION)

31      ASIA PACIFIC CLEAR CELL MARKET BY BRAND 2015-2024 ($ MILLION)

32      REST OF THE WORLD CLEAR CELL MARKET BY BRAND 2015-2024 ($ MILLION)

33      UNITED STATES KIDNEY CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

34      CANADA KIDNEY CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

35      UK CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

36      UK CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

37      FRANCE CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

38      FRANCE CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

39      GERMANY CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

40      GERMANY CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

41      SPAIN CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

42      SPAIN CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

43      ROE CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

44      ROE CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

45      CHINA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

46      CHINA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

47      INDIA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

48      INDIA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

49      JAPAN CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

41      JAPAN CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

42      AUSTRALIA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

43      AUSTRALIA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

41      ROAPAC CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

42      ROAPAC CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

43      LATIN AMERICA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

44      LATIN AMERICA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

45      MENA CANCER MARKET BY TYPE 2015-2024 ($ MILLION)

46      MENA CANCER MARKET BY BRAND 2015-2024 ($ MILLION)

 

LIST OF FIGURE

1   GLOBAL CLEAR CELL MARKET TYPE MARKET 2015-2024 ($ MILLION)

2   GLOBAL PAPILLARY MARKET TYPE MARKET 2015-2024 ($ MILLION)

3   GLOBAL CHROMOPHOBE MARKET TYPE MARKET 2015-2024 ($ MILLION)

4   GLOBAL ONCOCYTIC MARKET TYPE MARKET 2015-2024 ($ MILLION)

5   GLOBAL COLLECTING DUCT MARKET TYPE MARKET 2015-2024 ($ MILLION)

6   GLOBAL NEXAVAR (SORAFENIB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

7   GLOBAL SUTENT (SUNITINIB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

8   GLOBAL AFINITOR (EVEROLIMUS) MARKET BRAND MARKET 2015-2024 ($ MILLION)

9   GLOBAL VOTRIENT (PAZOPANIB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

10 GLOBAL AVASTIN (BEVACIZUMAB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

11 GLOBAL INLYTA (AXITINIB) MARKET BRAND MARKET 2015-2024 ($ MILLION)

12 GLOBAL TORISEL (TEMSIROLIMUS) MARKET   BRAND MARKET 2015-2024 ($ MILLION)

13 GLOBAL PROLEUKIN (ALDESLEUKIN) MARKET BRAND MARKET 2015-2024 ($ MILLION)

14 UNITED STATES CANCER DRUG MARKET 2015-2024 ($ MILLION)

15 CANADA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

16 UNITED KINGDOM KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

17 FRANCE KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

18 GERMANY KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

19 SPAIN KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

20 ROE KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

21 CHINA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

22 INDIA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

23 JAPAN KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

24 AUSTRALIA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

25 ROAPAC KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

26 LATIN AMERICA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

27 MENA KIDNEY CANCER DRUG MARKET 2015-2024 ($ MILLION)

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample


UPCOMING REPORTS

No upcoming reports available under this subcategory.
credit card

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 8390547755

Email: info@occamsresearch.com

 

 

Go To Top
viewthroughconversion